Top

Published in:

01-08-2012 | Viewpoint

Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes

Authors: Jonathan B Mitchem, David G DeNardo

Published in: Breast Cancer Research | Issue 4/2012

Abstract

Tumor-derived factors, such as proinflammatory cytokines, can increase the hospitality of metastatic sites by recruiting and activating leukocytes to perform supporting roles during metastatic dissemination. These same cytokines, however, are natural danger signals for the immune system and as such can induce anti-tumor immune responses by both adaptive and innate immune cells. The outcome of tumor-derived inflammatory cytokines is probably closely related to the exact repertoire of factors produced by each tumor. Several recent studies have investigated these seemingly contradictory roles of tumor-derived CCL2 with significant clinical implications.

Available only for authorised users

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005, 438: 820-827. 10.1038/nature04186.CrossRefPubMedPubMedCentral

Wels J, Kaplan RN, Rafii S, Lyden D: Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008, 22: 559-574. 10.1101/gad.1636908.CrossRefPubMedPubMedCentral

Psaila B, Lyden D: The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009, 9: 285-293. 10.1038/nrc2621.CrossRefPubMedPubMedCentral

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011, 475: 222-225. 10.1038/nature10138.CrossRefPubMedPubMedCentral

Chen Q, Zhang XH, Massague J: Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011, 20: 538-549. 10.1016/j.ccr.2011.08.025.CrossRefPubMedPubMedCentral

Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011, 20: 300-314. 10.1016/j.ccr.2011.08.012.CrossRefPubMedPubMedCentral

Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM: CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010, 70: 109-118. 10.1158/0008-5472.CAN-09-2326.CrossRefPubMed

Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM: Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell. 2009, 16: 183-194. 10.1016/j.ccr.2009.06.017.CrossRefPubMedPubMedCentral

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G⁺Ly6C⁺ granulocytes. Proc Natl Acad Sci USA. 2010, 107: 21248-21255. 10.1073/pnas.1015855107.CrossRefPubMedPubMedCentral

10.

Soria G, Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267: 271-285. 10.1016/j.canlet.2008.03.018.CrossRefPubMed

Title: Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes
Authors: Jonathan B Mitchem
David G DeNardo
Publication date: 01-08-2012
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 4/2012
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr3149

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Do not jump too quickly to conclusions

Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer

Is the tide turning against breast screening?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer